Concepedia

Abraham Anderson

AA

Statistics

Publications

33

Citations

5.7K

H-Index

24

Active since

1998

Affiliations

Amgen (United States)(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Roswell Park Comprehensive Cancer Center

Huntsman Cancer Institute

Abraham Anderson is an author at Amgen (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1998–2025

33

Publications

33

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov et al. · Cell · 2017 · 1.5K citations · Full text

Medicine, Immunology, Oncology +12

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 261 citations

Medicine, Oncology, Pharmacology +15

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Julien Dilly, Megan T. Hoffman, Laleh Abbassi et al. · Cancer Discovery · 2024 · 234 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

Patrick Y. Wen, David Schiff, Timothy F. Cloughesy et al. · Neuro-Oncology · 2011 · 169 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 33